This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: The McCoy Group
Ikonisys, a leader in cell-based diagnostic solutions including their signature oncoFISH® cervical test, hires veteran business strategist and financial executive James A. Bento as their new chief executive officer. Bento is charged with taking the company to national prominence, leveraging their leadership in FISH-based laboratory testing in the Northeast.
New Haven, CT (PRWEB) December 12, 2012
Ikonisys, a leader in cell-based diagnostic solutions including its signature oncoFISH® cervical test, has appointed veteran business strategist and financial executive, James A. Bento as chief executive officer. Bento is charged with leveraging Ikonisys' prominence in diagnostic equipment manufacturing and FISH-based laboratory testing in the Northeast to propel the company to national prominence.
"We are pleased to have Jim take the lead at Ikonisys," said Mario Mauri, a member of the Ikonisys Board of Directors. "In his previous roles as president and chief financial officer for various companies, he has provided guidance on sales, personnel, operations, technology, profits and facilities. He has consulted with high-profile organizations including Pfizer and has ties throughout the biotech and bioscience industries."
Ikonisys is known for its patented CellOptics® platform and Ikoniscope®/Ikonisoft® Robotic Microscopy System, which are the keystones to a growing list of proprietary laboratory tests and services that are transforming healthcare throughout the region.
"It is very exciting to work with a company whose innovations can truly change the face of healthcare not only in the United States, but also around the world," said Bento. "Our oncoFISH cervical test is truly an amazing advance in health care for women. When used in conjunction with current practice guidelines for cervical cancer screening, oncoFISH cervical can accurately detect specific genetic changes that can assist the physician in predicting a woman's probability of progressing to a more serious stage of cervical disease."
"Without this test, physicians simply do not have a precise enough tool to help assess cervical disease risk for women with abnormal Pap smears," continued Bento. "Ikonisys is operating Ikonisys Clinical Laboratories (ICL), which are certified by both Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). Our laboratory offers the oncoFISH cervical test as a laboratory-developed test. Ikonisys is informing women and their doctors about potential utility of oncoFISH cervical in helping to better manage an abnormal Pap diagnosis and minimize both patient anxiety and possibly unnecessary treatment. The educational process is undertaken by ICL’s own medical sales team, as well as by our partner clinical laboratories. Expanding this educational process is part of my mission with our team."
According to the National Institutes of Health, approximately 60 million Pap tests are performed annually in the United States, of which about 4.2 million are abnormal. Presently, Ikonisys is contracted to provide this follow-up test to approximately 6,000 women per year with that number increasing fast, as more and more physicians learn about the clinical efficacy of the oncoFISH cervical test.
In addition to oncoFISH cervical testing, Ikonisys has developed and is marketing FDA-cleared diagnostic systems that use the Ikoniscope/Ikonisoft system for bladder and breast cancers. This rare cancer cell detection system reduces the subjectivity and fatigue associated with manual test analysis, allowing laboratories to be more productive.
"Our Chief Technology Officer Triantafyllos Tafas and Vice President of Biology Michael Kilpatrick are extraordinary industry leaders and innovators," said Bento. "Over the past decade, they have developed, tested and patented ground-breaking medical technology. It's now our job to commercialize these products and services so that the benefits can be experienced by physicians and patients throughout the country, and eventually around the world. I look forward to this challenge."
For more information on Ikonisys and its products and services, visit ikonisys.com
or call 203-776-0791.
Headquartered in New Haven, CT, Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing disease with an emphasis in cancer diagnosis. Since 1999, Ikonisys has developed and refined its CellOptics® and Ikoniscope/Ikonisoft platforms, the basis for Ikonisys' products and laboratory services. These products enable large and regional reference labs, hospitals, research institutions and practice groups to reduce the risk of human error, lower costs, and expand test volume capacity, even during an industry-wide shortage of trained technical personnel. Most exciting, through its integration of intelligent imaging, microscopy, biology and informatics, Ikonisys is laying the foundation for detecting a single cell and identifying its molecular signals, a long-term key to maximizing patient health and wellness.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10223869.htm